The cell lines were responsive to treatment with a JAK inhibitor, which highlights both the importance of dysregulated STAT3 in this aggressive lymphoma and suggests a therapeutic benefit to targeting the JAK/STAT pathway [36]. Here, STAT3 is linked to lymphoma.